On November 20, Scholar Rock Holding Corp rose 4.6% in Regular Trading, trading at $50.12 per share, with turnover of $35.13 million.
A clear recent catalyst is continued analyst support: J.P. Morgan maintained a Buy rating on November 17 and set a $64 price target, reinforcing a constructive stance after the company’s latest quarterly report.
That earnings release showed a Q3 loss of $0.81 per share, better than the expected $0.85 loss, while revenue of about $0.57 million to $0.60 million also exceeded expectations. The company ended September with $413.6 million in cash, cash equivalents, and marketable securities. The result followed September’s FDA approval of Isembyld for certain spinal muscular atrophy patients and the launch of US commercial shipments, giving investors both a fresh commercial story and a solid liquidity backdrop.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments